Toll-like receptor and type I interferon pathway

The "Toll-like receptor and type I interferon pathway" is not a single molecule or canonical therapeutic target but refers to a complex signal transduction cascade primarily involving toll-like receptors (TLRs) and their downstream activation of type I interferon responses. TLRs are a family of pattern recognition receptors that detect pathogen-associated molecular patterns and initiate signaling through adaptor proteins such as MyD88 and TRIF. This leads to activation of transcription factors (NF-κB, IRFs) and results in the production of pro-inflammatory cytokines and type I interferons (IFN-α/β). The pathway is central to both antiviral defense and the broader innate immune response but encompasses multiple distinct proteins, each with its own function, therapeutic relevance, and potential as a target[1][2][3][4]. Key contextual notes: - The query refers to a pathway, not to a single protein, receptor, or druggable target. Thus, it is incorrect as a "target" in the molecular pharmacology sense. Each TLR (e.g., Toll-like receptor 3, Toll-like receptor 4) and downstream molecules (e.g., MyD88, TRIF, IRF3, TBK1) can be considered discrete targets individually[1][2][3][4]. - There are approved and investigational drugs that may target various points in this pathway for treatment of infection, cancer, and autoimmune diseases, but the pathway as a whole is not itself directly targeted. - Patient biomarkers, safety concerns, and drugs are generally associated with individual components, not with the combined pathway as an entity.

Other names

TLR and type I IFN pathwayTLR/IFN pathwayTLR signaling and type I interferon signaling